Corvus Pharmaceuticals CRVS Total Equity
Total Equity at other companies
Other financials
Where this comes from
Reported directly by Corvus Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:StockholdersEquity.
The official record: Corvus Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Corvus Pharmaceuticals's total equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Corvus Pharmaceuticals's total equity?
- Corvus Pharmaceuticals (CRVS) reported total equity of $240.68M in Q1 2026.
- How has Corvus Pharmaceuticals's total equity changed year-over-year?
- Corvus Pharmaceuticals's total equity increased by 387.9% year-over-year, from $49.33M to $240.68M.
- What is the long-term trend for Corvus Pharmaceuticals's total equity?
- Over 5 years (2020 to 2025), Corvus Pharmaceuticals's total equity has grown at a -3.2% compound annual growth rate (CAGR), from $72.15M to $61.21M.
- What does total equity mean?
- Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.